Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ResMed

ResMed's Quarterly Earnings Preview: What You Need to Know

ResMed is expected to release its fiscal second-quarter earnings this month, and analysts project a double-digit profit growth.

Barchart · Jan 3, 2025

Is ResMed Stock Outperforming the Nasdaq?

ResMed has outpaced the broader Nasdaq Composite index over the past year, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart · Dec 17, 2024

ResMed Stock: Is Wall Street Bullish or Bearish?

Although ResMed has outperformed relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart · Nov 25, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Fabric face mask to help apnoea sufferers rest easy

After double-digital sales growth last quarter, ASX-listed medical device maker ResMed has launched a product its CEO had been dreaming about for a decade.

AAP · Nov 18, 2024

ResMed's Q1 2025 Earnings: What to Expect

ResMed is scheduled to report its first-quarter earnings later this month, and analysts project a double-digit rise in its bottom line.

Barchart · Oct 14, 2024

Is ResMed Stock Outperforming the S&P 500?

ResMed has recently outperformed the S&P 500, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart · Sep 20, 2024

ResMed Stock: Analyst Estimates & Ratings

Despite ResMed’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart · Aug 27, 2024

Read news from The Economist, FT, and more,
with one subscription

Weight-loss drugs not lights out for ResMed: CEO

Sleep apnoea device manufacturer ResMed has continued to see revenue and net income grow, despite short-sellers claiming weight loss drugs threaten its market.

AAP · Aug 2, 2024

Five Stocks With Solid Growth History and a Promising Outlook

Five reasonably priced stocks with solid growth history and a good chance of delivering earnings even if the economy softens.

Kiplinger · Jul 8, 2024

After Blowout Earnings, This Dividend Stock Still Looks Cheap

Despite its remarkable post-earnings rally, here's a dividend stock that still carries a bargain tag.

Barchart · May 7, 2024

FDA deems ResMed's respiratory device recall as most severe

Learn about the recent recall of ResMed's respiratory devices by the US FDA, deemed as the most serious. Find out more about the implications and what acti...

Australians losing sleep over cost of living crisis

Australians should take sleep seriously as a survey marking World Sleep Day sheds light on the impact of financial pressures, experts say.

AAP · Mar 16, 2023

ResMed rings up record $1B in sales in latest quarter led by connected sleep apnea devices

For the past 18 months, ResMed Chief Executive Mick Farrell has been publicly outspoken in urging that medical devices get priority access to semiconductors amid global chip shortages coming out of the pandemic.

Tribune News Service · Jan 28, 2023

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022

Upgrades

Benzinga · Oct 20, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Jul 1, 2022

Here's How Much You Would Have Made Owning ResMed Stock In The Last 20 Years

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 11.66% on an annualized basis producing an average annual return of 18.75%. Currently, ResMed has a market capitalization of $30.88 billion.

Benzinga · Jun 22, 2022

Analyzing ResMed's Short Interest

ResMed's (NYSE:RMD) short percent of float has risen 5.62% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 0.94% of all regular shares that are available for trading.

Benzinga · Jun 15, 2022

Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years

ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 9.9% on an annualized basis producing an average annual return of 16.19%. Currently, ResMed has a market capitalization of $29.81 billion.

Benzinga · Jun 14, 2022

ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How

ResMed Inc (NYSE:RMD) has agreed to acquire privately-held MEDIFOX DAN, a Germany-based provider of out-of-hospital software solutions, from Hg, a software and services investor. MEDIFOX DAN's clinical, financial, and operational solutions are similar to ResMed's U.S. SaaS brands, MatrixCare and Brightree. MEDIFOX DAN's German customer base is complementary to the customers of ResMed's U.S.-based…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Jun 6, 2022

Analyst Ratings for ResMed

Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:

Benzinga · Jun 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

Upgrades

Benzinga · Jun 2, 2022

If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today

ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of $30.35 billion.

Benzinga · May 3, 2022

ResMed Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters.

Benzinga · Apr 29, 2022

What 3 Analyst Ratings Have To Say About ResMed

Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Apr 29, 2022

ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract

ResMed Inc's (NYSE:RMD) Q3 FY22 sales increased by 12% Y/Y (+14% on a constant currency basis) to $864.5 million, missing the consensus of $897 million. The revenue growth was driven by increased demand for sleep and respiratory care devices and an increased demand following an ongoing recall of rival Koninklijke Philips N.V. (NYSE:PHG) products. ResMed…

Benzinga · Apr 27, 2022

Earnings Outlook For ResMed

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an earnings per share (EPS) of $1.42.

1 2 3

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.